OverviewSuggest Edit

Founded in 1986 by two former employees of Abbott France, Theradiag has been dedicated, at first, to distributing in vitro diagnostics, specifically for autoimmune diseases. With more than 25 years experience of developing, manufacturing, and marketing innovative in-vitro diagnostics, Theradiag is now strengthening its presence in theranostics. Our new name, Theradiag, illustrates this approach. With CE marking in 2010 and the launch in 2011 of the first Lisa-Tracker kits, we are expanding this panel by developing and launching new kits. Our goal is to offer clinicians and patients a wide range of biotherapy monitoring kits. We have built the foundations for this new activity based on our knowledge of autoimmune diseases. In the coming months, we will be extending our offer to assist in the monitoring of biotherapies in other treatment areas, such as infectious diseases and cancer. We will also continue to develop our traditional activity in IVD, and specifically autoimmunity and innovative oncogenetic diagnostics. This technological and innovative evolution will allow Theradiag to better serve its clients and contribute to improving the bio-therapeutic treatments of today and the future.
TypePublic
Founded1990
HQCroissy-Beaubourg, FR
Websitetheradiag.com

Latest Updates

Employees (est.) (Jul 2021)57
Share Price (Sept 2021)€2.1(+3%)
Cybersecurity ratingCMore

Key People/Management at Theradiag

Bertrand de Castelnau

Bertrand de Castelnau

Chief Executive Officier & Director
Sylvie Bratel

Sylvie Bratel

Independent Director
Pierre Morgon

Pierre Morgon

Chairman of the Board of Directors
Vincent Fert

Vincent Fert

Director
Simon Daviere

Simon Daviere

Theranostic Business Unit Director
Sylvain Lecomte

Sylvain Lecomte

IVD & Services Business Unit Director
Show more

Theradiag Office Locations

Theradiag has an office in Croissy-Beaubourg
Croissy-Beaubourg, FR (HQ)
14 Rue Ambroise Croizat
Show all (1)

Theradiag Financials and Metrics

Theradiag Revenue

Market capitalization (9-Sept-2021)

17.6m

Closing stock price (9-Sept-2021)

2.1
Theradiag's current market capitalization is €17.6 m.
Show all financial metrics

Theradiag Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Theradiag Online and Social Media Presence

Embed Graph

Theradiag Blogs

19/07/2021: Bertrand de Castelnau, CEO of Theradiag, presents the company’s news and objectives

Click on the image below to find the interview with Bertrand de Castelnau, CEO of Theradiag, who presents the main assets of the company, the major events of H1 2021 and Theradiag’s medium-term objectives:  Or click on this link to access the interview

19/07/2021: Theradiag reports revenue of €5.5 million for the first half of 2021, up 12.5%

H1 2021 revenue growth of 14.7 % for Theranostics Theranostics activity up 33.6% in the United States Good performance for IVD, with growth of 10.4% Croissy-Beaubourg, July 19, 2021, 7.30 am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Ther…

10/06/2021: Theradiag: report of the extraordinary general meeting on second call of June 10, 2021

Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces that the Extraordinary General Meeting held today in camera on 2nd convocation was able…

31/05/2021: Theradiag announces the launch of HUMABDIAG, a large-scale research project targeting the bioproduction of monoclonal antibodies in Tours

Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces the launch of HUMABDIAG, a large-scale antibody bioproduction research project in Tours…

10/05/2021: Theradiag announces the adoption of all ordinary resolutions at the Shareholders’ Meeting of May 6, 2021

The Extraordinary Shareholders’ Meeting will be held on June 10, 2021 on the second call   Croissy-Beaubourg, May 10, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announces that its Shareholders’ Meeting has adop…

Theradiag announces its 2020 full-year results

·         Revenue growth of 8.0%, driven by the excellent performance of Theranostics, up 15.5%, and the substantial expansion in activity in the United States, up 34.0% ·         Substantial improvement of 44.5% in the net result before non-recurring items ·         R&D investments and developm…
Show more

Theradiag Frequently Asked Questions

  • When was Theradiag founded?

    Theradiag was founded in 1990.

  • Who are Theradiag key executives?

    Theradiag's key executives are Bertrand de Castelnau, Sylvie Bratel and Pierre Morgon.

  • How many employees does Theradiag have?

    Theradiag has 57 employees.

  • Who are Theradiag competitors?

    Competitors of Theradiag include Yashraj Biotechnology, DDL Diagnostic Laboratory and Response Biomedical.

  • Where is Theradiag headquarters?

    Theradiag headquarters is located at 14 Rue Ambroise Croizat, Croissy-Beaubourg.

  • Where are Theradiag offices?

    Theradiag has an office in Croissy-Beaubourg.

  • How many offices does Theradiag have?

    Theradiag has 1 office.